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At a Glance Commentary: 
Although inhaled triple pharmacologic therapy is recommended for patients with 
advanced chronic obstructive pulmonary disease and is often used clinically as step-
up treatment, few randomized controlled trials have assessed the benefit of triple 
therapy compared with dual inhaled corticosteroid/long-acting β2-agonist therapy. 
Results from the FULFIL study demonstrated the clinical benefit of once-daily 
fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) combination therapy using 
a single inhaler compared with twice-daily budesonide/formoterol (BUD/FOR) 
combination therapy. Once-daily FF/UMEC/VI improved lung function and health-
related quality of life, as well as reducing exacerbation frequency, compared with 
twice-daily BUD/FOR.  
Online Data Supplement: This article has an online data supplement, which is 
accessible from this issue's table of content online at www.atsjournals.org. 
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Abstract 
Rationale: Randomized data comparing triple therapy with dual inhaled 
corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic 
obstructive pulmonary disease (COPD) are limited. 
Objectives: We compared the effects of once-daily triple therapy on lung function 
and health-related quality of life with twice-daily ICS/LABA therapy. 
Methods: FULFIL was a randomized, double-blind, double-dummy study comparing 
24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 
100 µg/62.5 µg/25 µg; ELLIPTA® inhaler) with twice-daily ICS/LABA therapy 
(budesonide/formoterol 400 µg/12 µg; Turbuhaler®). A patient subgroup remained on 
blinded treatment for up to 52 weeks. Co-primary endpoints were change from 
baseline in trough forced expiratory volume in 1 second (FEV1) and in St George’s 
Respiratory Questionnaire (SGRQ) Total score, at Week 24. 
Measurements and Main Results: In the intent-to-treat population (N = 1,810) at 
Week 24 for triple therapy (n = 911) and ICS/LABA therapy (n = 899): mean change 
from baseline in FEV1 was 142 mL (95% confidence interval [CI], 126,158) and -29 
mL (95% CI, -46,-13), respectively; mean change from baseline SGRQ was -6.6 
units (95% CI, -7.4,-5.7) and -4.3 units (95% CI, -5.2,-3.4), respectively. For both 
endpoints, the between-group differences were statistically significant (P < 0.001). 
There was a statistically significant reduction in moderate/severe exacerbation rate 
with triple versus ICS/LABA therapy (35% reduction, 95% CI, 14,51; P = 0.002). The 
safety profile of triple therapy reflected the known profiles of the components. 
Conclusions: These results support the benefits of single inhaler triple therapy 
compared with ICS/LABA therapy, in patients with advanced COPD. 
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Introduction 
The use of inhaled triple pharmacologic therapy by patients with chronic obstructive 
pulmonary disease (COPD) is common; a UK study found that after 2 years, 46% of 
patients initially prescribed a long-acting bronchodilator and 39% of those prescribed 
an inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) or ICS plus long-acting 
muscarinic antagonist (LAMA) progressed to triple therapy (1). In a US study, 25.5% 
of patients with COPD, who had received at least one LAMA, LABA, ICS, or 
phosphodiesterase-4 inhibitor, received triple therapy within 2 years of being 
diagnosed (2). The Global Initiative for Chronic Obstructive Lung Disease strategy 
document recommends inhaled triple pharmacologic therapy (ICS/LAMA/LABA) for 
patients with advanced COPD with persistent symptoms and risk of exacerbations 
(3).  
Despite the current widespread use of triple therapy, there are few randomized 
controlled trials demonstrating a sustained benefit on lung function and patient 
reported outcome measures compared with ICS/LABA alone (4). Recently, a once-
daily single inhaler triple therapy of fluticasone furoate/umeclidinium/vilanterol 
(FF/UMEC/VI) 100 µg/62.5 µg/25 µg has been developed for patients with moderate 
to very severe COPD. This ‘closed triple’ therapy may offer clinically important 
improvements in lung function and quality of life compared with ICS/LABA dual 
therapy, as well as eliminating the need for delivering the medications using multiple 
inhalers. Single inhaler triple therapy may reduce the risk of medication errors and 
may help to ensure that a patient receives all three medications. 
FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed 
trIpLe therapy) is the first study to compare once-daily single inhaler triple therapy 
(ICS/LABA/LAMA) with twice-daily dual therapy (ICS/LABA) in patients with 
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advanced, symptomatic COPD, who are at risk of exacerbations. It was designed in 
part to support the registration of once-daily FF/UMEC/VI in Europe and other 
countries globally. In consultation with European regulators, the sponsor was asked 
to provide a comparison with an ICS/LABA dual combination product indicated to 
treat patients with COPD, which was well known and well understood by physicians. 
BUD/FOR was chosen as it is a commonly prescribed medication for patients with 
COPD. The study provides comparative information not just between classes of 
therapies but also between different molecules with different dosing regimens. 
 
FULFIL was specifically designed to have a close resemblance to real-world 
clinical practice. It compared a once-daily triple pharmacologic therapy to a current 
standard-of-care ICS/LABA, and the run-in period allowed patients to continue on 
their pre-study maintenance therapy up to randomization to mimic switch scenarios 
in clinical practice. FULFIL also allowed inclusion of patients with commonly 
observed comorbidities who are often excluded from other trials. The patient’s 
perspective was carefully evaluated using a health-related quality of life co-primary 
endpoint. Some of the results have been previously reported in the form of an 
abstract (5). 
 
 
Methods 
Trial Design and Oversight 
FULFIL was a phase III, randomized, double-blind, double-dummy, parallel-group, 
multicenter study (ClinicalTrials.gov number, NCT02345161; GSK study 
CTT116853). Patients were randomized to receive 24 weeks of once-daily 
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FF/UMEC/VI (100 µg/62.5 µg/25 µg) using a single ELLIPTA® inhaler and twice-daily 
placebo using the Turbuhaler®, or twice-daily budesonide/formoterol (BUD/FOR) 
(400 µg/12 µg) using the Turbuhaler® and once-daily placebo using the ELLIPTA® 
inhaler. Twice-daily BUD/FOR using the Turbuhaler® was the comparator, as this 
ICS/LABA is commonly used in this patient population. All patients took one 
inhalation from the ELLIPTA® inhaler in the morning and two inhalations (one in the 
morning and one in the evening) from the Turbuhaler® to minimize the impact of 
different dosing regimens. 
There was a 2-week run-in period, during which medications at screening were 
unchanged, followed by a 24-week treatment period. A subset of the first 430 
patients to enroll in the trial and consent to longer-term treatment remained on 
blinded study treatment for up to 52 weeks. To minimize loss of data, patients who 
permanently discontinued study treatment (but did not withdraw consent) were not 
required to withdraw from the study, but could continue to have certain safety and 
efficacy assessments conducted. 
The primary objectives were to evaluate the effects of once-daily single inhaler 
triple therapy (FF/UMEC/VI) on lung function and health-related quality of life 
compared with twice-daily dual ICS/LABA therapy (BUD/FOR) at 24 weeks. 
The institutional review boards for human studies approved the protocol and 
written consent was obtained from the subjects or their surrogates as required by the 
institutional review boards. 
 
Study Endpoints 
The co-primary endpoints were change from baseline in trough forced expiratory 
volume in 1 second (FEV1) and change from baseline in St George’s Respiratory 
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Questionnaire (SGRQ) Total score, at Week 24. Supportive analyses for the primary 
endpoints included: proportion of patients with a clinically meaningful change from 
baseline in trough FEV1 (≥ 100 mL) and change from baseline SGRQ Total score 
(≥ 4 unit decrease); change from baseline in Evaluating Respiratory Symptoms in 
COPD score (E-RS: COPD; formerly EXACT RS) over 24 weeks and the proportion 
of responders. Population pharmacokinetic analyses were conducted on serial and 
sparse blood samples collected from a subset of patients (n = 74) to assess FF, 
UMEC, and VI systemic exposure from a single inhaler.  
Efficacy and safety endpoints were analyzed up to Week 24 in the intent-to-
treat (ITT) population and up to Week 52 in the extension (EXT) population. 
 
Patients 
FULFIL enrolled patients with COPD aged ≥ 40 years defined as Global Initiative for 
Chronic Obstructive Lung Disease Group D: FEV1 < 50% and COPD Assessment is 
TestTM ≥ 10, or patients with FEV1 ≥ 50–< 80% and COPD Assessment Test
TM ≥ 10, 
and either ≥ 2 moderate exacerbations in the past year or ≥ 1 severe exacerbation in 
the past year. Patients were required to be receiving daily maintenance therapy for 
COPD for ≥ 3 months. Patients were excluded if they had a current diagnosis of 
asthma causing their symptoms, or unresolved pneumonia or severe COPD 
exacerbation. Demographic and disease characteristics were recorded at screening. 
 
Efficacy Assessments 
Spirometry was performed in all patients at baseline and at Weeks 2, 4, 12, 24, and 
at Weeks 36 and 52 in the EXT population, using standardized equipment according 
to the American Thoracic Society-European Respiratory Society criteria (6). The 
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SGRQ for COPD patients was completed using a patient-held eDiary at Day 1 and at 
Weeks 4 and 24 (and Week 52 for the EXT population). Potential COPD 
exacerbations were identified based on symptoms reported using the eDiary, which 
triggered follow-up with the investigator, who confirmed any exacerbations based on 
an interaction with the patient. Mild exacerbations were defined as worsening 
symptoms of COPD that were self-managed by the patient (e.g. increase in albuterol 
use) and not associated with the use of corticosteroids or antibiotics. A moderate 
exacerbation was defined as having worsening symptoms of COPD that required 
treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation 
was defined as worsening symptoms of COPD that required treatment with in-patient 
hospitalization. The E-RS: COPD questionnaire was completed each evening using 
the eDiary. 
 
Safety Assessments 
The incidence of adverse events (AEs), serious AEs (SAEs), pneumonia and 
supporting radiography, cardiovascular events including pre-specified major 
cardiovascular events analysis, bone fractures, and other AEs of special interest 
(AESI) were evaluated in the study (AESI are listed in Table E1 in the online data 
supplement).  
 
Statistical Analyses 
Statistical analyses were carried out using SAS Version 9.3. Sample size was 
calculated based on the co-primary endpoints and previous experience with drugs of 
these classes. The ITT population, stratified by smoking status, comprised all 
randomized patients, excluding those who were randomized in error who did not 
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receive a dose of study medication. The EXT population comprised the subset of 
patients in the ITT population who were enrolled into the 52-week extension phase. 
The co-primary endpoints were analyzed using mixed model repeated measures and 
were adjusted for multiplicity using the Hochberg method.  
 
Further details of the methods are provided in the online data supplement. 
 
 
Results 
Patients 
In total, 1,810 patients were included in the ITT population (FF/UMEC/VI, n = 911; 
BUD/FOR, n = 899) and 430 in the EXT population (FF/UMEC/VI, n = 210; 
BUD/FOR, n = 220) (Figure E1 in the online data supplement). Overall, 94% of 
patients completed the study and 90% completed the study on investigational 
treatment; premature treatment discontinuations were most frequently due to patient 
decision (4%), AE, or lack of efficacy (both 3%). Patient and disease characteristics 
at baseline for the ITT and EXT populations are shown in Table 1. COPD 
medications used during the study run-in are provided in Table E2 in the online data 
supplement. 
 
Co-Primary Endpoints 
In the ITT population, FF/UMEC/VI demonstrated clinically meaningful improvements 
from baseline in trough FEV1 at all time points over the 24-week treatment period 
(Figure 1A; Table 2). At Week 24, the mean change from baseline in trough FEV1 
was 142 mL (95% confidence interval [CI], 126,158) for FF/UMEC/VI and -29 mL 
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(95% CI, -46,-13) for BUD/FOR; the difference between FF/UMEC/VI and BUD/FOR 
was statistically significant (171 mL; 95% CI, 148,194; P < 0.001) (Table 2). The 
treatment differences ranged from 123 to 171 mL and were statistically significant in 
favor of FF/UMEC/VI at all time points (P < 0.001).  
In the ITT population, at Week 24, clinically meaningful improvements in SGRQ 
Total score were observed in both treatment groups. The change from baseline in 
SGRQ was -6.6 units (95% CI, -7.4,-5.7) with FF/UMEC/VI and -4.3 (95% CI, -5.2,-
3.4) with BUD/FOR. The between-treatment difference in improvement in SGRQ 
Total score was statistically significant for FF/UMEC/VI (-2.2 units; 95% CI, -3.5,-1.0; 
P < 0.001) compared with BUD/FOR (Table 2). 
Similar findings in change from baseline in trough FEV1 were observed in the 
EXT population at Week 52 (Figure 1B; Table 2). The mean change from baseline in 
trough FEV1 was 126 mL (95% CI, 92,159) for FF/UMEC/VI and -53 mL (95% CI, -
87,-20) for BUD/FOR. The mean change from baseline in SGRQ Total score in the 
EXT population was -4.6 units (95% CI, -6.5,-2.6) with FF/UMEC/VI and -1.9 units 
(95% CI, -3.9,0.1) with BUD/FOR, and although the between-treatment difference 
was of a similar magnitude to that observed in the ITT population, it did not reach 
statistical significance (Table 2). 
 
Selected Secondary and Other Endpoints 
In the ITT population at Week 24, an increase of ≥ 100 mL from baseline in trough 
FEV1 was achieved by a larger proportion of patients in the FF/UMEC/VI group (453; 
50%) than in the BUD/FOR group (184; 21%). The odds ratio (OR) of achieving 
versus not achieving this increase was statistically significant in favor of FF/UMEC/VI 
(OR, 4.03; 95% CI, 3.27,4.97; P < 0.001). 
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A larger proportion of patients in the FF/UMEC/VI group (448; 50%) than in the 
BUD/FOR group (368; 41%) experienced a clinically meaningful improvement from 
baseline (≥ 4 unit decrease) in SGRQ Total score in the ITT population at Week 24. 
The OR of response versus non-response was statistically significant in favor of 
FF/UMEC/VI (OR, 1.41; 95% CI, 1.16,1.70; P < 0.001) (Table 2). 
The incidence of moderate/severe COPD exacerbations over the 24-week 
treatment period was 10% (n = 95) and 14% (n = 126) for FF/UMEC/VI and 
BUD/FOR, respectively. The mean annualized rate of moderate/severe 
exacerbations was 0.22 and 0.34 for FF/UMEC/VI and BUD/FOR, respectively, and 
the reduction in the annualized rate was statistically significant (35%; 95% CI, 
14,51%; P = 0.002) based on data up to 24 weeks in the ITT population (Table 3). 
Similar statistically significant results were observed for mild/moderate/severe 
exacerbations (Table 3). Fewer patients were hospitalized for exacerbations in the 
FF/UMEC/VI treatment group (12 [1%]) than in the BUD/FOR group (22 [2%]).  
For the ITT population, at each 4-week interval over the 24-week treatment 
period, FF/UMEC/VI produced greater reductions from baseline in E-RS: COPD total 
score compared with BUD/FOR and the treatment differences were statistically 
significant (P < 0.001) (Figure 2). The ORs for response versus non-response for 
each 4-week interval were statistically significant in favor of FF/UMEC/VI (OR 
ranging 1.59,1.76; P < 0.001). Similar results were observed for each E-RS: COPD 
subscale (breathlessness; cough and sputum; chest symptoms). 
The results for the secondary and other endpoints described here were also 
observed up to 52 weeks in the EXT population (see respective tables and figures). 
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Safety Analyses 
The incidence of on-treatment AEs in the ITT population up to Week 24 was 38.9% 
in the FF/UMEC/VI group and 37.7% in the BUD/FOR group; the most common AEs 
were nasopharyngitis (7% and 5% for FF/UMEC/VI and BUD/FOR, respectively) and 
headache (5% and 6% for FF/UMEC/VI and BUD/FOR, respectively) (Table 4). A 
similar pattern was observed in the EXT population up to Week 52; the most 
common AEs were nasopharyngitis (11% and 10% for FF/UMEC/VI and BUD/FOR, 
respectively) and headache (8% and 10% for FF/UMEC/VI and BUD/FOR, 
respectively). COPD worsening was one of the most common AEs in the BUD/FOR 
group (10%), but was less common in the FF/UMEC/VI group (2%) in the EXT 
population up to Week 52. 
For FF/UMEC/VI and BUD/FOR, respectively: the incidence of on-treatment 
SAEs in the ITT population up to Week 24 was 5.4% and 5.7%; the most common 
on-treatment SAEs were COPD exacerbation (1.3% and 2.3%) and pneumonia 
(1.0% and 0.3%). There were 12 on-treatment deaths in this study (six in each 
treatment group), which was in line with expectations for patients with advanced 
COPD and multiple comorbidities. The incidence of adjudicated on-treatment non-
fatal SAEs in the ITT population was 4.9% in the FF/UMEC/VI group and 5.2% in the 
BUD/FOR group. Of these (for FF/UMEC/VI and BUD/FOR, respectively), COPD 
exacerbations (1.5% and 2.4%) and pneumonia and/or respiratory tract infection 
without COPD exacerbation (0.9% and 0.3%) were the most common. An overview 
of the rate of drug-related AEs and SAEs is provided in the Results section of the 
online data supplement. 
The incidence of pre-specified AESIs in the ITT population was also 
investigated. For FF/UMEC/VI and BUD/FOR, respectively: cardiovascular effects 
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were reported by 4.3% and 5.2% of patients and the incidence of pneumonia was 
2.2% and 0.8% in the ITT population up to Week 24 (Table 4). 
The incidence of on-treatment SAEs in the EXT population was 10.0% in the 
FF/UMEC/VI group and 12.7% in the BUD/FOR group. In the EXT population up to 
Week 52, for FF/UMEC/VI and BUD/FOR, respectively, cardiovascular effects as 
AESI were reported by 8.6% and 10.0% of patients, and the incidence of pneumonia 
as an AESI was 1.9% and 1.8% (Table 4).  
The incidence of major cardiovascular events was 0.4% and 0.8% in the ITT 
population up to Week 24, and 2.4% and 0.9% in the EXT population up to Week 52, 
for FF/UMEC/VI and BUD/FOR, respectively. There were no clinically significant 
differences between treatment groups in vital signs, electrocardiograms, Holter 
findings, or laboratory values. 
Population pharmacokinetic analyses showed that systemic drug levels of FF, 
UMEC, and VI following FF/UMEC/VI administration using a single inhaler (triple 
therapy) were low and within the range observed following dual therapy (FF/VI and 
UMEC/VI) and monotherapy (FF, UMEC, and VI) (7, 8). 
 
Discussion 
Our results show that once-daily FF/UMEC/VI offered clinically meaningful and 
statistically significant improvements at Week 24 in lung function and health-related 
quality of life compared with BUD/FOR. The improvements in health-related quality 
of life were reflected in the consistent reduction in total symptoms, measured using 
the E-RS: COPD. At each 4-weekly time point, FF/UMEC/VI demonstrated greater 
symptom reduction than BUD/FOR. Clinically meaningful and statistically significant 
reductions in exacerbation rates for patients with COPD were also observed with 
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FF/UMEC/VI compared with BUD/FOR, at Week 24. Importantly, the benefits of 
FF/UMEC/VI on lung function, health-related quality of life, and exacerbation rate 
were sustained over 52 weeks in the EXT population. The magnitude of the 
between-treatment difference in SGRQ Total score between treatment groups at 
Week 52 failed to achieve statistical significance, possibly due to the smaller size of 
this subgroup. The lung function findings reported here are in keeping with the 
results of shorter studies of triple therapy using FF/VI and UMEC in two separate 
inhalers (4, 9).  
The safety profile of FF/UMEC/VI, including the systemic exposure, was in line 
with the known profiles of the component drugs, and findings from the 52-week EXT 
population suggest that there are no cumulative adverse effects from once-daily 
FF/UMEC/VI. While the incidence of pneumonia was higher with FF/UMEC/VI than 
with BUD/FOR in the ITT population up to 24 weeks, it was similar between the two 
groups in the smaller EXT population at 52 weeks. The incidence of pneumonia with 
FF/UMEC/VI observed here is consistent with reports from other 24-week studies of 
FF/VI for COPD, which reported incidences of up to 2% (10, 11), and studies of 
BUD/FOR for COPD (12, 13). The incidence of pneumonia is also similar to that 
observed in another study of ICS/LABA/LAMA therapy for COPD, in which 
pneumonia occurred in 3% of patients in both the triple therapy and the ICS/LABA 
comparator arms (14) and is less than the incidence reported in 52-week studies of 
FF/VI (15) and BUD/FOR (16). No excess risk of pneumonia with FF or VI either 
alone or in combination, compared with placebo, was found in the SUMMIT study 
(although SUMMIT included patients with moderate airflow limitation and only 39% 
had a history of exacerbations) (17). 
Although this study was focused on non-exacerbation outcomes and the 
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proportion of patients with exacerbations in the overall population was low, there 
were clear efficacy benefits in favor of FF/UMEC/VI on these outcome measures in 
both the ITT and EXT populations.  
FULFIL was designed to be as inclusive as possible, allowing patients with 
COPD who also had significant cardiovascular disease to be enrolled. Furthermore, 
patients remained on their usual standard medications during the run-in and were 
not artificially required to withdraw medications. This meant the study population may 
more closely reflect the real-world population of patients with COPD and increases 
the generalizability of the study findings. FULFIL was also designed to minimize data 
loss, by enabling data collection to continue following treatment discontinuation. All 
SAE reports were independently adjudicated, and a chest radiograph was required 
for all patients with suspected pneumonia or a moderate/severe exacerbation, which 
improved the characterization of safety findings.  
This study compared an ICS/LABA/LAMA (FF/UMEC/VI) combination with an 
ICS/LABA (BUD/FOR) using different dosing regimens (once daily vs. twice daily) in 
different inhalers. The double-dummy study design aimed to mitigate some of these 
differences, so the results reported are a direct comparison of the products rather 
than the addition of a LAMA to ICS/LABA. However, there is evidence supporting the 
value of incremental LAMA therapy (4, 9, 14, 18). Two randomized, 3-month studies 
showed clinically relevant improvements in lung function with UMEC plus FF/VI, 
compared with placebo plus FF/VI, in patients with moderate-to-very severe COPD 
(9). The TRILOGY study (14) showed that triple therapy compared with ICS/LABA 
had a modest benefit with a reduction in exacerbations and an improvement in 
health-related quality of life; however, this appeared to wane as the study continued. 
A post-hoc analysis of four trials that assessed UMEC or placebo plus ICS/LABA 
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(including the two studies described previously) showed that triple therapy improved 
lung function and health-related quality of life, and reduced the risk of exacerbations 
compared with ICS/LABA (4). Of note, in FULFIL, the benefits of FF/UMEC/VI over 
BUD/FOR seem substantially greater and more persistent than those seen in the 
comparison of beclomethasone dipropionate/formoterol/glycopyrronium bromide with 
beclomethasone dipropionate/formoterol (14). This could be due to the advantages 
of once-daily versus twice-daily dosing, the differences in the individual components, 
or a combination of the two. Further study is needed to clarify the drivers of these 
differences. 
 
Results from the FULFIL study demonstrated the clinical value of triple therapy 
using FF/UMEC/VI, compared with dual BUD/FOR therapy, for symptomatic patients 
with advanced COPD who are at risk of exacerbations. Once-daily single inhaler 
triple therapy provides a straightforward dosing option for patients with COPD and 
this reduction in polypharmacy using multiple inhalers may reduce the likelihood of 
inhaler use errors, although all inhaler types may be associated with errors in use 
(19–21). Single inhaler triple therapy offers clinically important benefits in lung 
function, health-related quality of life, and reduction in risk of exacerbation, which 
were also observed over 52 weeks. 
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Figure Legends 
 
Figure 1. Mean change from baseline in trough FEV1 over (A) 24 weeks (ITT 
population) and (B) 52 weeks (EXT population). The bars indicate 95% confidence 
intervals. BUD = budesonide; CI = confidence interval; EXT = extension; FEV1 = 
forced expiratory volume in 1 second; FF = fluticasone furoate; FOR = formoterol; 
ITT = intent-to-treat; LS = least squares; UMEC = umeclidinium; VI = vilanterol. 
 
 
Figure 2. Mean change from baseline in 4-weekly E-RS total score (ITT population). 
The bars indicate 95% confidence intervals. BUD = budesonide; CI = confidence 
interval; E-RS = Evaluating Respiratory Symptoms; FF = fluticasone furoate; FOR = 
formoterol; ITT = intent-to-treat; LS = least squares; UMEC = umeclidinium; VI = 
vilanterol. 
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Tables and Figures 
Table 1. Patient Characteristics at Baseline (ITT and EXT Populations)* 
Characteristic 
ITT Population (24 Weeks) 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 911) 
BUD/FOR 
400/12 µg 
(n = 899) 
Total 
 
(N = 1,810) 
Age, yr 64.2 (8.56) 63.7 (8.71) 63.9 (8.64) 
Female, n (%) 233 (26) 236 (26) 469 (26) 
Current smokers, n (%) 400 (44) 394 (44) 794 (44) 
Smoking pack-years  39.5 (21.87) 39.2 (22.15) 39.4 (22.00) 
Cardiovascular risk factors†, n (%) 599 (66) 602 (67) 1,201 (66) 
Moderate/severe COPD 
exacerbation in previous 12 
months, n (%) 
   
0 313 (34) 317 (35) 630 (35) 
1 252 (28) 253 (28) 505 (28) 
≥ 2 346 (38) 329 (37) 675 (37) 
History of pneumonia, n (%) 87 (10) 99 (11) 186 (10) 
FEV1 absolute, mL  1349 (0.46) 1339 (0.48) 1344 (0.47) 
FEV1 predicted, %  45.5 (12.97) 45.1 (13.64) 45.3 (13.30) 
SGRQ Total score  51.8 (16.29) 50.8 (16.73) – 
E-RS: COPD 13.20 (5.828) 12.97 (5.928) – 
 EXT Population (52 Weeks) 
FF/UMEC/VI 
100/62.5/25 µg 
BUD/FOR 
400/12 µg 
Total 
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(n = 210) (n = 220) (N = 430) 
Age, yr 63.7 (7.76) 63.3 (8.43) 63.5 (8.10) 
Female, n (%) 53 (25) 58 (26) 111 (26) 
Current smokers, n (%) 95 (45) 97 (44) 192 (45) 
Smoking pack-years 39.8 (19.92) 39.6 (23.12) 39.7 (21.59) 
Cardiovascular risk factors†, n (%) 144 (69) 152 (69) 296 (69) 
Moderate/severe COPD 
exacerbation in previous 12 
months, n (%) 
   
0 62 (30) 72 (33) 134 (31) 
1 77 (37) 79 (36) 156 (36) 
≥ 2 71 (34) 69 (31) 140 (33) 
History of pneumonia, n (%) 18 (9) 20 (9) 38 (9) 
FEV1 absolute, mL  1425 (0.50) 1368 (0.51) 1396 (0.51) 
FEV1 predicted, %  47.1 (13.30) 45.4 (14.85) 46.2 (14.13) 
SGRQ Total score 53.0 (16.14) 50.8 (15.49) – 
E-RS: COPD 13.54 (5.439) 13.00 (5.576) – 
Definition of abbreviations: BUD = budesonide; COPD = chronic obstructive 
pulmonary disease; E-RS: COPD = Evaluating Respiratory Symptoms in COPD; 
EXT = extension; FEV1 = forced expiratory volume in 1 second; FF = fluticasone 
furoate; FOR = formoterol; ITT = intent-to-treat; SD = standard deviation; SGRQ = St 
George’s Respiratory Questionnaire; UMEC = umeclidinium; VI = vilanterol. 
*Data are mean (SD) unless otherwise stated.  
†Cardiovascular risk factors included, but were not limited to, hypertension, 
hypercholesterolemia, coronary heart disease, and diabetes mellitus.  
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Table 2. Trough FEV1 and SGRQ Responses (ITT and EXT Populations) 
 
ITT Population (24 Weeks) 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 911) 
BUD/FOR 
400/12 µg 
(n = 899) 
Trough FEV1, mL   
LS mean at Week 24 
95% CI 
1,418 
1,401,1,434 
1,247 
1,230,1,263 
LS mean change from 
baseline 
95% CI 
 
142 
126,158 
 
-29 
-46,-13 
FF/UMEC/VI vs. BUD/FOR 
difference (95% CI) 
P-value 
 
171 (148,194) 
<0.001 
Proportion of trough FEV1 
responders*, n 
 
907 
 
892 
Responders, % (n) 50 (453) 21 (184) 
FF/UMEC/VI vs. BUD/FOR 
OR (95% CI) 
P-value 
 
4.03 (3.27,4.97) 
<0.001 
Change from baseline in 
SGRQ Total score, n 
 
846 
 
791 
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LS mean at Week 24 
95% CI 
44.7 
43.8,45.5 
46.9 
46.0,47.8 
LS mean change 
95% CI 
-6.6 
-7.4,-5.7 
-4.3 
-5.2,-3.4 
FF/UMEC/VI vs. BUD/FOR 
difference (95% CI) 
P-value 
 
-2.2 (-3.5,-1.0) 
<0.001 
Proportion of responders†, 
n 
 
904 
 
893 
Responders, n (%) 448 (50) 368 (41) 
FF/UMEC/VI vs. BUD/FOR 
OR (95% CI) 
P-value 
 
1.41 (1.16,1.70) 
<0.001 
 
EXT Population (52 Weeks) 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 210) 
BUD/FOR 
400/12 µg 
(n = 220) 
Trough FEV1, mL   
LS mean at Week 52 
95% CI 
1,429 
1,395,1,462 
1,250 
1,216,1,284 
LS mean change from 
baseline 
 
126 
 
-53 
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95% CI 92,159 -87,-20 
FF/UMEC/VI vs. BUD/FOR 
difference (95% CI) 
P-value 
 
179 (131,226) 
<0.001 
Proportion of trough FEV1 
responders*, n 
  
Responders, % (n) 46 (96) 16 (34) 
FF/UMEC/VI vs. BUD/FOR 
OR (95% CI) 
P-value 
 
4.79 (3.02,7.61) 
<0.001 
Change from baseline in 
SGRQ Total score, n 
182 174 
LS mean at Week 52 
95% CI 
47.3 
45.3,49.3 
50.0 
48.0,52.0 
LS mean change 
95% CI 
-4.6 
-6.5,-2.6 
-1.9 
-3.9,0.1 
FF/UMEC/VI vs. BUD/FOR 
difference (95% CI) 
P-value 
 
-2.7 (-5.5,0.2) 
0.065 
Proportion of responders†, 
n 
209 219 
Responders, n (%) 91 (44) 73 (33) 
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FF/UMEC/VI vs. BUD/FOR 
OR (95% CI) 
P-value 
 
1.50 (1.01,2.24) 
0.046 
Definition of abbreviations: BUD = budesonide; CI = confidence interval; EXT = 
extension; FEV1 = forced expiratory volume in 1 second; FF = fluticasone furoate; 
FOR = formoterol; ITT = intent-to-treat; LS = least squares; OR = odds ratio; SGRQ 
= St George’s Respiratory Questionnaire; UMEC = umeclidinium; VI = vilanterol. 
*Response was defined as a trough FEV1 of ≥ 100 mL above baseline. 
†Response was defined as an SGRQ Total score change of ≥ 4 units below baseline. 
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Table 3. Annual Exacerbation Rates (ITT and EXT Populations) 
Annual Rate of 
COPD 
Exacerbations 
Up to 24 Weeks Up to 52 Weeks 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 911) 
BUD/FOR 
400/12 µg 
(n = 899) 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 210) 
BUD/FOR 
400/12 µg 
(n = 220) 
Population, n 907 892 210 219 
Moderate and severe exacerbations 
Mean rate 0.22 0.34 0.20 0.36 
Ratio (95% CI); 
P-value 
0.65 (0.49,0.86); 0.002 0.56 (0.37,0.85); 0.006 
Reduction in 
rate, % (95% 
CI) 
35 (14,51) 44 (15,63) 
Mild, moderate, and severe exacerbations 
Mean rate 0.25 0.39 0.22 0.40 
Ratio (95% CI); 
P-value 
0.65 (0.50,0.84); <0.001 0.55 (0.37,0.81); 0.003 
Reduction in 
rate, % (95% 
CI) 
35 (16,50) 45 (19,63) 
Definition of abbreviations: BUD = budesonide; CI = confidence interval; COPD = 
chronic obstructive pulmonary disease; EXT = extension; FF = fluticasone furoate; 
FOR = formoterol; ITT = intent-to-treat; UMEC = umeclidinium; VI = vilanterol. 
Ratios and P-values are calculated for FF/UMEC/VI vs. BUD/FOR.  
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Table 4. Adverse Events and Adverse Events of Special Interest (ITT and EXT 
Populations) 
Adverse Events 
Occurring in ≥ 2% of 
Patients in Either 
Population, n (%) 
ITT Population  
(24 Weeks) 
EXT Population  
(52 Weeks) 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 911) 
BUD/FOR 
400/12 µg 
(n = 899) 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 210) 
BUD/FOR 
400/12 µg 
(n = 220) 
Nasopharyngitis 64 (7) 43 (5) 23 (11) 22 (10) 
Headache 44 (5) 53 (6) 17 (8) 22 (10) 
URTI 20 (2) 19 (2) 6 (3) 10 (5) 
COPD 15 (2) 23 (3) 5 (2) 22 (10) 
Back pain 19 (2) 18 (2) 4 (2) 5 (2) 
Arthralgia 17 (2) 13 (1) 5 (2) 6 (3) 
Pneumonia 19 (2) 7 (< 1) 4 (2) 4 (2) 
Pharyngitis 15 (2) 9 (1) 5 (2) 1 (< 1) 
Oropharyngeal pain 9 (< 1) 10 (1) 6 (3) 1 (< 1) 
Dizziness – – 1 (< 1) 6 (3) 
Blood pressure 
increased 
4 (< 1) 8 (< 1) 0 4 (2) 
Dyspnea – – 0 4 (2) 
Vertigo – – 0 4 (2) 
Adverse Events of Special Interest 
Cardiovascular effects 39 (4.3) 47 (5.2) 18 (8.6) 22 (10.0) 
Pneumonia 20 (2.2) 7 (0.8) 4 (1.9) 4 (1.8) 
Local steroid effects* 19 (2.1) 24 (2.7) 8 (3.8) 7 (3.2) 
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Anticholinergic 
syndrome* 
16 (1.8) 17 (1.9) 4 (1.9) 12 (5.5) 
Hypersensitivity 10 (1.1) 10 (1.1) 3 (1.4) 1 (0.5) 
Hyperglycemia/ 
diabetes** 
5 (0.5) 4 (0.4) 0 4 (1.8) 
Decreased bone 
mineral density 
4 (0.4) 6 (0.7) 1 (0.5) 1 (0.5) 
LRTI (excluding 
pneumonia) 
3 (0.3) 4 (0.4) 1 (0.5) 0 
Ocular effects* 1 (0.1) 4 (0.4) – – 
Urinary retention 1 (0.1) 0 – – 
Asthma/ 
bronchospasm 
0 1 (0.1) – – 
Definition of abbreviations: BUD = budesonide; COPD = chronic obstructive 
pulmonary disease; EXT = extension; FF = fluticasone furoate; FOR = formoterol; 
ITT = intent-to-treat; LRTI = lower respiratory tract infection; UMEC = umeclidinium; 
URTI = upper respiratory tract infection; VI = vilanterol. *These terms are derived 
from the Standardized Medical Dictionary for Regulatory Activities (MedDRA).   
**New-onset diabetes. 
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Methods 
Patients 
Patients were enrolled from approximately 200 study centers globally. Additional 
criteria for excluding patients from the FULFIL study were: chronic obstructive 
pulmonary disease (COPD) caused by α1-antitrypsin deficiency, other significant 
respiratory disorders, lung resection within 12 months of screening, or other clinically 
significant diseases. Patients who had pneumonia or severe COPD exacerbations 
were excluded if the events had not resolved within 14 days of screening. Patients 
with a respiratory tract infection that had not resolved within 7 days of screening, an 
abnormal chest X-ray, or an abnormal and clinically significant 12-lead 
electrocardiogram (ECG) finding were also excluded. 
Patients were randomized using the interactive voice recognition system 
(Registration and Medication Ordering System [RAMOS]), stratified by smoking 
status. 
 
Efficacy Assessments 
COPD exacerbations were defined as: mild (self-managed by the patient by 
increasing rescue medication use); moderate (required treatment with oral/systemic 
corticosteroids and/or antibiotics, without hospitalization); or severe (required in-
patient hospitalization). 
 
Daily symptoms were recorded in electronic diaries (eDiaries). The eDiary alerted 
the patient to contact their investigator if they had worsening symptoms over three 
consecutive days, and the patients were instructed to contact their investigator if they 
received this alert. Investigators also received an alert. Data were automatically 
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downloaded from the eDiary and transferred to a portal that could be accessed by 
the investigators. An interaction between the patient and the investigator was 
required to allow a physician to determine whether changes in symptoms were 
simply normal variation in the disease, or necessitated further therapy. Thus, the 
diagnosis of an exacerbation required clinical judgment combined with reported 
symptoms, mimicking clinical practice.  
 
Safety Assessments 
Patients recorded adverse events (AEs) and any medications using a diary 
worksheet and details were transcribed to the electronic case report form. ECG 
measurements, vital signs, and hematology and clinical chemistry parameters were 
recorded. COPD exacerbations were an expected disease-related outcome; thus, 
they were not recorded as an AE, unless they met the definition of a serious adverse 
event (SAE). All SAEs reported during the study were adjudicated by an independent 
clinical endpoint committee. Adverse events of special interest were defined a priori 
to evaluate potential AEs typically associated with the pharmacologic classes of 
inhaled corticosteroids, long-acting muscarinic antagonist, and long-acting β2-agonist 
(Table E1). 
 
Statistical Analyses 
Based on the co-primary endpoints and previous experience with the drugs, sample 
size was calculated to be 688 patients per treatment group, which provided at least 
90% power to detect a between-treatment difference of 80 mL for trough forced 
expiratory volume in 1 second, assuming a standard deviation (SD) of 240 mL, and 
2.5 units for St George’s Respiratory Questionnaire Total score, assuming an SD of 
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12 units, at 24 weeks at the 1% significance level. It was estimated that 30% of 
patients would discontinue treatment without being assessed at Week 24 and 
therefore 900 randomized patients were required for each treatment group. 
Covariates used in the analysis of the co-primary endpoints included treatment 
group, smoking status, geographical region, visit, baseline value, and baseline-by-
visit and treatment group-by-visit interactions. 
Least squares (LS) means and LS mean change from baseline with standard 
errors and 95% confidence intervals were calculated. The number of on-treatment 
moderate/severe exacerbations and the number of mild/moderate/severe 
exacerbations were analyzed using a generalized linear model assuming a negative 
binomial distribution. Average scores for the Evaluating Respiratory Symptoms in 
COPD over 4-week intervals were analyzed using mixed model repeated measures. 
Secondary and other efficacy analyses were not adjusted for multiplicity. 
 
 
Results 
Safety Analyses 
Drug-related AEs (assessed by the investigator) were reported by 5% of patients in 
the intent-to-treat population, with no single event occurring in more than 1% of 
patients in either group. Drug-related SAEs occurred in < 1% of patients and there 
were no drug-related deaths. 
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Table E1. List of Evaluated Adverse Events of Special Interest 
 
AESI Group AESI Subgroup Sub-SMQ 
Adrenal suppression*   
Anticholinergic syndrome† 
(SMQ) 
  
Asthma/bronchospasm 
(SMQ) 
  
Cardiovascular effects Cardiac arrhythmia Arrhythmia-related 
investigations, signs and 
symptoms (SMQ) 
Bradyarrhythmia terms, 
nonspecific (SMQ) 
Conduction defects (SMQ) 
Disorders of sinus node 
function (SMQ) 
Cardiac arrhythmia terms, 
nonspecific (SMQ) 
Supraventricular 
tachyarrhythmias (SMQ) 
Tachyarrhythmia terms, 
nonspecific (SMQ) 
Ventricular 
tachyarrhythmias (SMQ) 
Cardiac failure (SMQ)  
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Ischemic heart disease 
(SMQ) 
 
Hypertension (SMQ)  
Central nervous system 
hemorrhages and 
cerebrovascular 
conditions (SMQ) 
 
Ocular effects† Glaucoma (SMQ)  
Lens disorder (SMQ)  
Decreased bone mineral 
density and associated 
fractures‡ 
  
Effects on potassium*   
Gastrointestinal obstruction 
(SMQ) 
  
Hyperglycemia/new onset 
diabetes mellitus (SMQ) 
  
Hypersensitivity*   
Local steroid effects*,†   
Pneumonia and LRTI Pneumonia*  
LRTI excluding 
pneumonia* 
 
Tremor*   
Urinary retention*   
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Definition of abbreviations: AESI = adverse events of special interest; LRTI = lower 
respiratory tract infection; SMQ = Standardized Medical Dictionary for Regulatory 
Activities Query. 
*Selected Medical Dictionary for Regulatory Activities Preferred Terms. 
†
 These terms are derived from the Standardized Medical Dictionary for Regulatory 
Activities (MedDRA). “Anticholinergic syndrome” is derived from the broad version of 
the Standardized MedDRA query (SMQ) called “Anticholinergic syndrome (SMQ)”. 
This includes 50 preferred terms such as agitation, anhidrosis, ataxia, dry mouth, dry 
eye, and mydriasis. “Ocular effects” is derived from the broad version of “Glaucoma 
(SMQ)” (74 terms) and the “Lens disorders (SMQ)” (38 terms), including terms such 
as glaucoma, cataracts, eye pain, intraocular pressure increased, halo vision, vision 
blurred, and visual acuity reduced. “Local steroid effects” includes a list of 19 
preferred terms such as oral candidiasis, mucocutaneous candidiasis, dry throat, and 
dysphonia. 
‡Osteoporosis/osteopenia SMQ plus selected Medical Dictionary for Regulatory 
Activities Preferred Terms.  
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Table E2. COPD Medications Taken During Screening by ≥ 5 Patients in Either 
Treatment Group 
Medication Combination* 
Full Medication Combination† 
Patients, n (%) 
FF/UMEC/VI 
100/62.5/25 µg 
(n = 911) 
BUD/FOR 
400/12 µg 
(n = 899) 
Total 
N = 1,810 
ICS + LABA 
ICS + LABA 
ICS + LABA + short-acting 
anticholinergic + short-acting β2 
agonist 
ICS + LABA short-acting 
anticholinergic 
268 (29) 
252 (28) 
9 (< 1) 
 
 
3 (< 1) 
259 (29) 
241 (27) 
6 (< 1) 
 
 
5 (< 1) 
527 (29) 
493 (27) 
15 (< 1) 
 
 
8 (< 1) 
ICS + LABA + LAMA 
ICS + LABA + LAMA 
ICS + LABA + LAMA + short-acting 
anticholinergic + short-acting β2 
agonist 
ICS + LABA + LAMA + oxygen 
ICS + LABA + LAMA + mucolytics 
257 (28) 
220 (24) 
11 (1) 
 
 
5 (< 1) 
5 (< 1) 
256 (28) 
221 (25) 
6 (< 1) 
 
 
8 (< 1) 
6 (< 1) 
513 (28) 
441 (24) 
17 (< 1) 
 
 
13 (< 1) 
11 (< 1) 
LABA + LAMA 
LABA + LAMA 
101 (11) 
89 (10) 
84 (9) 
77 (9) 
185 (10) 
166 (9) 
LAMA 
LAMA 
LAMA + short-acting anticholinergic 
79 (9) 
64 (7) 
8 (< 1) 
79 (9) 
70 (8) 
5 (< 1) 
158 (9) 
134 (7) 
13 (< 1) 
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+ short-acting β2 agonist 
LABA 
LABA 
LABA + short-acting anticholinergic 
37 (4) 
27 (3) 
6 (< 1) 
42 (5) 
30 (3) 
6 (< 1) 
79 (4) 
57 (3) 
12 (< 1) 
ICS + LABA + LAMA + xanthine 
ICS + LABA + LAMA + xanthine 
33 (4) 
18 (2) 
44 (5) 
31 (3) 
77 (4) 
49 (3) 
ICS + LABA + xanthine 
ICS + LABA + xanthine 
19 (2) 
13 (1) 
18 (2) 
16 (2) 
37 (2) 
29 (2) 
ICS 
ICS 
15 (2) 
14 (2) 
12 (1) 
11 (1) 
27 (1) 
25 (1) 
LABA + LAMA + xanthine 
LABA + LAMA + xanthine 
10 (1) 
9 (< 1) 
12 (1) 
7 (< 1) 
22 (1) 
16 (< 1) 
ICS + LAMA 
ICS + LAMA 
5 (< 1) 
3 (< 1) 
11 (1) 
11 (1) 
16 (< 1) 
14 (< 1) 
LAMA + xanthine 6 (< 1) 3 (< 1) 9 (< 1) 
Definition of abbreviations: BUD = budesonide; COPD = chronic obstructive 
pulmonary disease; FF = fluticasone furoate; FOR = formoterol; ICS = inhaled 
corticosteroid; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic 
antagonist; UMEC = umeclidinium; VI = vilanterol. 
*COPD respiratory medication class (RMC) combination based on the individual 
RMC and any combination of the RMCs: ICS, LABA, LAMA, Xanthine, and PDE4 
Inhibitors.  
†COPD RMC combination based on all RMCs. 
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Figure E1. Patient flow in the FULFIL study. BUD = budesonide; FF = fluticasone 
furoate; FOR = formoterol; ITT = intent-to-treat; UMEC = umeclidinium; VI = 
vilanterol. 
 
Page 44 of 44 AJRCCM Articles in Press. Published on 04-April-2017 as 10.1164/rccm.201703-0449OC 
 Copyright © 2017 by the American Thoracic Society 
